Thanks Daon
BMS - 'Relativity' trial data - PFS for Relatlimab/Opdivo is over double that of Opdivo mono.
A fantastic result!!
BMS CEO said in recent teleconference that they were excited by LAG-3 and now can see why. They have many more LAG-3 trials in progress at P1/2 stage. This is first completed P3 trial for LAG3/PD1 combo as a first line therapy.
They will now be in talks with FDA to 'fast track' above combo.
Whilst Relatilimab is a different mode of action (anti- LAG3 blocking) to that of Efti, we know that OS (durability) could be better statistically than PFS (see AIPAC initial PFS v OS data).
If TACTI-002 posters show improving data (combo's with Keytruda) then we are off to the races!
Competitive tension building......
Thanks DaonBMS - 'Relativity' trial data - PFS for...
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.010(2.94%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 33.5¢ | $1.941M | 5.551M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 183720 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 111555 | 27 |
View Market Depth
| Last trade - 15.42pm 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |